AVEO Pharmaceuticals
AVEO
AVEO was delisted on the 19th of January, 2023.
70 hedge funds and large institutions have $60M invested in AVEO Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 21 closing their positions.
5.11% more ownership
Funds ownership: 57.93% → 63.04% (+5.1%)
0% more call options, than puts
Call options by funds: $6K | Put options by funds: $6K
0% less capital inflows, than outflows
Capital inflows: $15.3M | Capital outflows: $15.4M
14% less funds holding
Funds holding: 81 → 70 (-11)
18% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 28
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
57% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Great Point Partners
Greenwich,
Connecticut
|
+$6.01M |
| 2 |
BlackRock Institutional Trust
San Francisco,
California
|
+$3.23M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.98M |
| 4 |
Visium Asset Management
New York
|
+$801K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$525K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Palo Alto Investors
Palo Alto,
California
|
-$4.17M |
| 2 |
MPM Asset Management
Boston,
Massachusetts
|
-$1.68M |
| 3 |
BlackRock Fund Advisors
San Francisco,
California
|
-$1.26M |
| 4 |
Oracle Investment Management
Greenwich,
Connecticut
|
-$1.18M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.14M |
AVEO Hedge Fund Activity: Q4 2013 in Review
70 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals (AVEO) for Q4 2013, worth a combined $60M — down 3.1% from $62M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of AVEO and 9 opened new positions — a net loss of 12 holders — while 28 trimmed existing stakes and 23 added.
The largest buyer was Great Point Partners, opening a new position worth an estimated $6.01M. The largest seller was Palo Alto Investors, cutting an estimated $4.17M.
- 70 institutional investors held AVEO Pharmaceuticals (AVEO) as of Q4 2013, down from 81 in Q3 2013.
- Funds reported $60M of AVEO Pharmaceuticals stock for Q4 2013, down 3.1% quarter-over-quarter.
- 9 funds opened new AVEO Pharmaceuticals positions in Q4 2013 and 21 closed out, a net change of -12 holders.
- The largest AVEO Pharmaceuticals buyer in Q4 2013 was Great Point Partners, an estimated $6.01M added.
- The largest AVEO Pharmaceuticals seller in Q4 2013 was Palo Alto Investors, an estimated $4.17M sold.
Based on aggregated 13F filings for Q4 2013.